FI964113A - Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö - Google Patents

Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö Download PDF

Info

Publication number
FI964113A
FI964113A FI964113A FI964113A FI964113A FI 964113 A FI964113 A FI 964113A FI 964113 A FI964113 A FI 964113A FI 964113 A FI964113 A FI 964113A FI 964113 A FI964113 A FI 964113A
Authority
FI
Finland
Prior art keywords
treatment
pharmaceutical composition
tardive dyskinesia
tardive
dyskinesia
Prior art date
Application number
FI964113A
Other languages
English (en)
Swedish (sv)
Other versions
FI964113A0 (fi
Inventor
Hajime Sasaki
Yohko Maeda
Kenji Hashimoto
Toshiya Inada
Yoshie Kitao
Original Assignee
Iyo Masaomi
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iyo Masaomi, Meiji Seika Kaisha filed Critical Iyo Masaomi
Publication of FI964113A publication Critical patent/FI964113A/fi
Publication of FI964113A0 publication Critical patent/FI964113A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI964113A 1994-04-15 1996-10-14 Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö FI964113A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7714694 1994-04-15
PCT/JP1995/000736 WO1995028177A1 (fr) 1994-04-15 1995-04-14 Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition

Publications (2)

Publication Number Publication Date
FI964113A true FI964113A (fi) 1996-10-14
FI964113A0 FI964113A0 (fi) 1996-10-14

Family

ID=13625663

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964113A FI964113A0 (fi) 1994-04-15 1996-10-14 Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö

Country Status (8)

Country Link
US (1) US5712282A (fi)
EP (1) EP0755685A4 (fi)
JP (1) JP3598116B2 (fi)
AU (1) AU2224195A (fi)
CA (1) CA2187086A1 (fi)
FI (1) FI964113A0 (fi)
NO (1) NO964330L (fi)
WO (1) WO1995028177A1 (fi)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
EP1218003A4 (en) * 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
WO2002045749A2 (en) * 2000-11-02 2002-06-13 Research Foundation Of City University Of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
IL162850A0 (en) * 2002-01-04 2005-11-20 Ford Henry Health System Nitric oxide donors for treatment of disease and injury
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148748A (ja) * 1983-02-10 1984-08-25 Takeda Chem Ind Ltd ノナペプチド
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬

Also Published As

Publication number Publication date
AU2224195A (en) 1995-11-10
US5712282A (en) 1998-01-27
EP0755685A1 (en) 1997-01-29
JP3598116B2 (ja) 2004-12-08
FI964113A0 (fi) 1996-10-14
NO964330D0 (no) 1996-10-11
NO964330L (no) 1996-10-11
EP0755685A4 (en) 2000-05-03
CA2187086A1 (en) 1995-10-26
WO1995028177A1 (fr) 1995-10-26

Similar Documents

Publication Publication Date Title
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
KR950703566A (ko) 티에노디아제핀 화합물 및 그의 의약 용도[thienodiazepine compound and medicinal use thereof]
FI961599A (fi) 1N-alkyyli-N-aryylipyrimidiiniamiineja ja niiden johdannaisia
FI973471A0 (fi) Pyratsol-4-yylibentsoyylijohdoksia ja niiden käyttö herbisideinä
BR1100824A (pt) Composto e composição farmacêutica
BR9500784A (pt) Composto e formulação farmacêutica
BR9506119A (pt) Composição farmacêutica e forma de dosagem farmacêutica unitária
NO20021172L (no) Farmasöytisk sammensetning
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
FI972245A0 (fi) Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät
BR9509688A (pt) Composto e composição farmacêutica
FI943734A0 (fi) Uudet makrolidit ja niiden käyttö
EE03783B1 (et) Farmatseutiline kompositsioon epitelioomide raviks ja antikeha või antikeha molekuli kasutamine
BR9507768A (pt) Composição farmacêutica
FI964113A (fi) Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
LV11727A (lv) Farmaceitiska kompozicija
FI973280A (fi) Farmaseuttinen koostumus
EE9800054A (et) Pürasool-4-üül-bensoüüli derivaadid ja nende kasutamine herbitsiididena
BR9605777A (pt) Composição farmacêutica
BR9505130A (pt) Composto e composiçao farmacêutica
BR9605131A (pt) Composição farmacêutica
ITMI950120A0 (it) Composizione farmaceutica contenente n-acetil-cisteina
BR1100838A (pt) Composto e composição farmacêutica
BR1100293A (pt) Composto e composição farmacêutica
BR1100809A (pt) Composto e composição farmacêutica